[go: up one dir, main page]

JOP20200137A1 - نظائر إنكريتين واستخداماتها - Google Patents

نظائر إنكريتين واستخداماتها

Info

Publication number
JOP20200137A1
JOP20200137A1 JOP/2020/0137A JOP20200137A JOP20200137A1 JO P20200137 A1 JOP20200137 A1 JO P20200137A1 JO P20200137 A JOP20200137 A JO P20200137A JO P20200137 A1 JOP20200137 A1 JO P20200137A1
Authority
JO
Jordan
Prior art keywords
incretin
isotopes
activity
receptors
gip
Prior art date
Application number
JOP/2020/0137A
Other languages
English (en)
Inventor
Qu Hongchang
Coskun Tamer
Alsina-Fernandez Jorge
Guo Lili
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200137A1 publication Critical patent/JOP20200137A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

يتعلق الاختراع الحالي بنظائر الإنكريتين التي لها نشاط عند كل من مستقبلات GIP، GLP-1 والجلوكاجون. تمتلك نظائر الإنكريتين ميزات بنائية تؤدي إلى الحصول على نشاط متوازن ومفعول طويل المدى عند كل من هذه المستقبلات. ويتم أيضًا تقديم طرق لعلاج أمراض مثل مرض السكري، اختلال الدهون في الدم، مرض الكبد الدهني، متلازمة التمثيل الغذائي، التهاب الكبد الدهني غير الكحولي والسِّمنة.
JOP/2020/0137A 2017-12-21 2018-12-14 نظائر إنكريتين واستخداماتها JOP20200137A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
PCT/US2018/065663 WO2019125938A1 (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
JOP20200137A1 true JOP20200137A1 (ar) 2022-10-30

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0137A JOP20200137A1 (ar) 2017-12-21 2018-12-14 نظائر إنكريتين واستخداماتها

Country Status (27)

Country Link
US (4) US11542313B2 (ar)
EP (2) EP4691555A2 (ar)
JP (3) JP6961838B2 (ar)
KR (2) KR102622642B1 (ar)
CN (1) CN111491658B (ar)
AR (1) AR113486A1 (ar)
AU (1) AU2018388962B2 (ar)
BR (1) BR112020010244A2 (ar)
CA (1) CA3084005C (ar)
CL (1) CL2020001635A1 (ar)
CO (1) CO2020006255A2 (ar)
CR (1) CR20200255A (ar)
DO (1) DOP2020000123A (ar)
EA (1) EA202091290A1 (ar)
EC (1) ECSP20032650A (ar)
FI (1) FI3727426T3 (ar)
IL (2) IL275468B1 (ar)
JO (1) JOP20200137A1 (ar)
MA (1) MA51288A (ar)
MX (2) MX2020006548A (ar)
MY (1) MY199143A (ar)
PE (2) PE20251598A1 (ar)
PH (1) PH12020551025A1 (ar)
SG (1) SG11202005606VA (ar)
TW (2) TWI744579B (ar)
UA (1) UA129012C2 (ar)
WO (1) WO2019125938A1 (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN111171134B (zh) * 2018-11-12 2023-08-15 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
IL293249A (en) * 2019-12-03 2022-07-01 Antag Therapeutics Aps Optimized gip peptide analogs
TWI795698B (zh) 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR121650A1 (es) * 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
JP2023550594A (ja) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
WO2022247701A1 (zh) * 2021-05-26 2022-12-01 联邦生物科技(珠海横琴)有限公司 多激动剂及其应用
WO2022268029A1 (zh) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
CA3223313A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
JP7804766B2 (ja) * 2021-11-19 2026-01-22 チアンスー ディユアン ファーマシューティカル カンパニー リミテッド ステープルペプチド及びその使用
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
CN120112280A (zh) 2022-08-29 2025-06-06 伊莱利利公司 用于口服递送的组合物
JP2025532991A (ja) * 2022-09-28 2025-10-03 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１／ｇｃｇ／ｇｉｐ三重受容体アゴニスト及びその使用
KR20250096895A (ko) 2022-10-05 2025-06-27 일라이 릴리 앤드 캄파니 인크레틴 합성을 위한 펩티드
AU2023385357A1 (en) * 2022-11-21 2025-06-05 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN121002051A (zh) * 2023-04-11 2025-11-21 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN121285571A (zh) * 2023-06-09 2026-01-06 太阳医药工业有限公司 Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法
TW202502808A (zh) 2023-07-14 2025-01-16 大陸商北京拓界生物醫藥科技有限公司 Glp-1、gip和gcg受體三激動劑及其應用
WO2025087353A1 (zh) * 2023-10-26 2025-05-01 齐鲁制药有限公司 具有多重激动活性的多肽及其应用
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
WO2025162423A1 (zh) * 2024-02-02 2025-08-07 杭州先为达生物科技股份有限公司 针对glp-1r、gipr和gcgr的三激动剂
WO2025264785A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2025264809A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2025264776A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
CN119978101B (zh) * 2024-07-30 2025-10-10 四川普康药业有限公司 多肽化合物及其应用
CN119823233A (zh) * 2025-03-18 2025-04-15 杭州思诺达医药科技有限责任公司 瑞他鲁肽的合成方法及瑞他鲁肽
CN120189527A (zh) * 2025-05-27 2025-06-24 南方医科大学第三附属医院（广东省骨科研究院） 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途
CN120623312B (zh) * 2025-06-26 2026-01-23 乐普健糖药业(重庆)有限公司 Glp-1、gip、gcg三重受体激动剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300035B1 (en) * 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
NZ595344A (en) 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
AU2011206979B2 (en) * 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
EP3065767B1 (en) * 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US10131702B2 (en) * 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI669309B (zh) * 2015-06-22 2019-08-21 美商美國禮來大藥廠 升糖素及ｇｌｐ－１共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EA038544B1 (ru) * 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN112469431A (zh) * 2018-07-23 2021-03-09 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
TW202523681A (zh) * 2018-07-23 2025-06-16 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
TWI764209B (zh) * 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2021150673A1 (en) * 2020-01-23 2021-07-29 Eli Lilly And Company Gip/glp1 co-agonist compounds
AU2024215381A1 (en) * 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof

Also Published As

Publication number Publication date
US20250059251A1 (en) 2025-02-20
WO2019125938A1 (en) 2019-06-27
PH12020551025A1 (en) 2021-09-06
JP6961838B2 (ja) 2021-11-05
AU2018388962B2 (en) 2020-11-19
CA3084005A1 (en) 2019-06-27
US12371465B2 (en) 2025-07-29
US20200331980A1 (en) 2020-10-22
SG11202005606VA (en) 2020-07-29
EP4691555A2 (en) 2026-02-11
KR102444783B1 (ko) 2022-09-19
US12365716B2 (en) 2025-07-22
IL275468B1 (en) 2026-01-01
NZ765277A (en) 2024-08-30
CL2020001635A1 (es) 2020-10-16
TW201938188A (zh) 2019-10-01
MX2020006548A (es) 2020-09-14
AU2018388962A1 (en) 2020-06-04
JP2021506955A (ja) 2021-02-22
MY199143A (en) 2023-10-17
PE20210162A1 (es) 2021-01-26
JP2022033724A (ja) 2022-03-02
AR113486A1 (es) 2020-05-06
EA202091290A1 (ru) 2020-09-10
JP7658877B2 (ja) 2025-04-08
KR20200088419A (ko) 2020-07-22
JP2025093970A (ja) 2025-06-24
TWI809515B (zh) 2023-07-21
DOP2020000123A (es) 2020-08-31
US20230203121A1 (en) 2023-06-29
MA51288A (fr) 2021-03-31
US11542313B2 (en) 2023-01-03
TWI744579B (zh) 2021-11-01
MX2024010201A (es) 2024-08-26
BR112020010244A2 (pt) 2020-10-13
TW202202518A (zh) 2022-01-16
EP3727426A1 (en) 2020-10-28
IL275468A (en) 2020-08-31
US20250313605A1 (en) 2025-10-09
UA129012C2 (uk) 2024-12-25
CN111491658B (zh) 2024-04-26
ECSP20032650A (es) 2020-07-31
PE20251598A1 (es) 2025-06-16
EP3727426B1 (en) 2025-11-26
CO2020006255A2 (es) 2020-05-29
IL325353A (en) 2026-02-01
CN111491658A (zh) 2020-08-04
TW202415675A (zh) 2024-04-16
KR20220133304A (ko) 2022-10-04
CA3084005C (en) 2024-01-02
KR102622642B1 (ko) 2024-01-10
CR20200255A (es) 2020-07-12
FI3727426T3 (fi) 2026-02-04

Similar Documents

Publication Publication Date Title
JOP20200137A1 (ar) نظائر إنكريتين واستخداماتها
JOP20200136A1 (ar) نظائر إنكريتين واستخداماتها
JO3686B1 (ar) جلوكان ومركبات مساعِدات glp-1 مشتركة
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016004907A (es) Analogos del glucagon.
PH12016500675A1 (en) Acylated glucagon analogues
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PH12015500531A1 (en) Glucagon analogues
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2017012864A (es) Analogo acilado del glucagon.
MX394179B (es) Liraglutida en afecciones cardiovasculares.